Researchers Mine Administrative Databases to Uncover Valuable Research Focused on Non-Prostate Genitourinary Cancer Treatments

PHILADELPHIA (January 11, 2019) — Readily available administrative databases are a cost-effective tool for investigating treatments for non-prostate genitourinary cancer and identifying research gaps and novel therapies, Fox Chase Cancer Center researchers reported in the 2018 edition of the journal Urologic Oncology: Seminars and Original Investigations.

The researchers, led by Alexander Kutikov, MD, FACS, chief of the Division of Urology and Urologic Oncology at Fox Chase, focused on finding comparative effectiveness research (CER) data about non-prostate genitourinary malignancies, such as renal cell carcinoma, bladder cancer, upper tract urothelial carcinoma, testicular cancer, and adrenal cancer.

Resources such as National Cancer Database (NCDB) and the Surveillance, Epidemiology and End Results database (SEER) are large-volume, prospectively maintained administrative clinical datasets that include claims data and are based on billing, procedural, and diagnosis codes, making it possible to glean CER insights more effectively.

Kutikov noted in the article that CER data is, “imperative for objective and balanced assessment of treatment outcomes.” When administrative databases are used to conduct CER, the resulting large-scale data analyses can, “potentially transcend limitations of small institutional datasets,” and be more cost-effective for researchers.

Prior to this review, prostate cancer was the primary focus of researchers using these larger administrative databases. The Fox Chase team’s goal was to review the currently available AD-CER research into treatments of non-prostate genitourinary cancers and produce summaries of CER objectives and outcomes.

“Given the costs and logistical barriers to obtaining high quality level I data, CER will continue to play a role in establishing fiscally efficient, outcome-based patient-centered care as clinical oncologic landscapes rapidly change,” Kutikov wrote.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427